PMID- 32334152
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20210301
IS  - 1879-0429 (Electronic)
IS  - 0958-1669 (Linking)
VI  - 65
DP  - 2020 Oct
TI  - Are dendritic cells the most appropriate therapeutic vaccine for patients with 
      ovarian cancer?
PG  - 190-196
LID - S0958-1669(20)30040-9 [pii]
LID - 10.1016/j.copbio.2020.03.003 [doi]
AB  - New treatments are urgently needed in patients with ovarian cancer (OC), as 
      diagnosis is delayed in many instances, resulting in 85% recurrence of the 
      disease following surgery and standard chemotherapy. OC is considered to be an 
      immunological type of cancer, despite its limited response to current 
      immunotherapy options, including vaccination. Thus, additional interventions may 
      improve their efficacy. Dendritic cells (DCs) are the most widely used cellular 
      vaccination therapy in patients with OC due to their crucial role in the 
      initiation and development of immune response. There are viable options for 
      DC-vaccination with a favorable toxicity profile, but specific alternatives 
      should consider the limited therapeutic effectiveness of DC-vaccination in OC 
      treatment. In this respect, B-cells and macrophages provide additional 
      possibilities that may be explored for immunotherapy. Here we consider the 
      current state-of-the-art of immunotherapy strategies for OC treatment and 
      evaluate their potential for future improvements.
CI  - Copyright (c) 2020 Elsevier Ltd. All rights reserved.
FAU - Martin-Lluesma, Silvia
AU  - Martin-Lluesma S
AD  - Center of Experimental Therapeutics, Ludwig Center for Cancer Research, 
      Department of Oncology, University of Lausanne, Lausanne 1011, Switzerland.
FAU - Graciotti, Michele
AU  - Graciotti M
AD  - Vaccine Development Laboratory, Ludwig Center for Cancer Research, University of 
      Lausanne, Lausanne 1011, Switzerland.
FAU - Grimm, Alizee J
AU  - Grimm AJ
AD  - Center of Experimental Therapeutics, Ludwig Center for Cancer Research, 
      Department of Oncology, University of Lausanne, Lausanne 1011, Switzerland.
FAU - Boudousquie, Caroline
AU  - Boudousquie C
AD  - Center of Experimental Therapeutics, Ludwig Center for Cancer Research, 
      Department of Oncology, University of Lausanne, Lausanne 1011, Switzerland.
FAU - Chiang, Cheryl L
AU  - Chiang CL
AD  - Vaccine Development Laboratory, Ludwig Center for Cancer Research, University of 
      Lausanne, Lausanne 1011, Switzerland.
FAU - Kandalaft, Lana E
AU  - Kandalaft LE
AD  - Center of Experimental Therapeutics, Ludwig Center for Cancer Research, 
      Department of Oncology, University of Lausanne, Lausanne 1011, Switzerland; 
      Vaccine Development Laboratory, Ludwig Center for Cancer Research, University of 
      Lausanne, Lausanne 1011, Switzerland. Electronic address: Lana.Kandalaft@chuv.ch.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200422
PL  - England
TA  - Curr Opin Biotechnol
JT  - Current opinion in biotechnology
JID - 9100492
RN  - 0 (Cancer Vaccines)
RN  - 0 (Vaccines)
SB  - IM
MH  - *Cancer Vaccines/therapeutic use
MH  - Dendritic Cells
MH  - Female
MH  - Humans
MH  - Immunotherapy
MH  - *Ovarian Neoplasms/therapy
MH  - *Vaccines
EDAT- 2020/04/26 06:00
MHDA- 2021/03/02 06:00
CRDT- 2020/04/26 06:00
PHST- 2019/12/30 00:00 [received]
PHST- 2020/03/10 00:00 [revised]
PHST- 2020/03/19 00:00 [accepted]
PHST- 2020/04/26 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
PHST- 2020/04/26 06:00 [entrez]
AID - S0958-1669(20)30040-9 [pii]
AID - 10.1016/j.copbio.2020.03.003 [doi]
PST - ppublish
SO  - Curr Opin Biotechnol. 2020 Oct;65:190-196. doi: 10.1016/j.copbio.2020.03.003. 
      Epub 2020 Apr 22.